Liver cancer is a malignancy with active angiogenesis and a complex immune microenvironment, and is one of the most common digestive system malignancies worldwide. Alfa Cytology is a global leader in cancer research. With our extensive experience and advanced platforms, our talented scientists provide one-stop solutions for liver cancer animal model development, efficacy evaluation, orthotopic liver model validation, intrahepatic dissemination and metastasis research, tumor immunology testing, anti-angiogenesis testing, liver histopathology testing, molecular mechanism testing, and PK/PD, based on client candidate drugs, treatment scenario, cell line characteristics, liver organ microenvironment, immune system requirements, administration route, and R&D stages. We also provide zebrafish experimental services and cell-based experimental services, covering diverse research needs from in vitro to in vivo and from high-throughput screening to mechanism validation.
Liver cancer is a malignant tumor originating from hepatocytes or biliary epithelium, with hepatocellular carcinoma (HCC) being the most common subtype and one of the most common digestive system malignancies worldwide. Liver cancer is characterized by active angiogenesis, frequent intrahepatic dissemination, a complex immune microenvironment, and prominent chronic disease background. Clinically, liver cancer is commonly managed based on stage, liver function status, and molecular background. Early HCC can be treated with surgical resection, ablation, and liver transplantation; advanced HCC relies more on TACE, anti-angiogenic agents, immune checkpoint inhibitors, and combination therapy. VEGF/VEGFR, FGFR, MET, GPC3, AFP, TROP2, and HER2 are important targets in current drug development. NASH-HCC and fibrosis background HCC differ from virus-related HCC in pathogenesis and treatment response. Common metastatic routes in liver cancer include intrahepatic dissemination, lung metastasis, and lymph node metastasis. Among these, intrahepatic dissemination and multifocal liver lesions are high-priority scenarios in translational research. The liver cancer immune microenvironment is characterized by Kupffer cells, liver sinusoidal endothelial cells, and myeloid cells, with complex immunosuppressive mechanisms.
Fig.1 Schematic representation of major signaling pathways involved in liver cancer. (Dimri, M., & Satyanarayana, A., 2020)
Therefore, liver cancer animal studies need to be differentially designed based on intrahepatic microenvironment, anti-angiogenesis requirement, target expression, immune system requirements, chronic disease background, and administration route, in order to better support candidate screening, efficacy evaluation, and clinical translation assessment.
Alfa Cytology has established a comprehensive solution platform for liver cancer animal experimental research, built around hepatocellular carcinoma (HCC) early efficacy screening, liver orthotopic microenvironment, intrahepatic dissemination, lung metastasis, chronic disease background carcinogenesis, immunotherapy, anti-angiogenesis combination, local therapy, and relapse/MRD scenarios. Leveraging this integrated platform, Alfa Cytology provides end-to-end services covering the full liver cancer research workflow.
Liver cancer drug development requires model selection based on therapeutic scenario, cell line characteristics, intrahepatic microenvironment, immune background, and administration route. Alfa Cytology provides integrated animal study solutions, from cell line selection to model validation, for small molecule targeted agents, anti-angiogenic agents, immune checkpoint inhibitors, ADCs, bispecifics, TCEs, CAR-T/NK, local delivery, TACE/ablation combination, radiotherapy combination, and anti-relapse programs.
Candidate Screening
Early screening typically requires rapid assessment of whether a candidate demonstrates in vivo antitumor signals. Alfa Cytology conducts TGI, RTV, PK/PD, and target inhibition evaluations using subcutaneous CDX models, providing data to support dose selection, dosing frequency, and candidate prioritization.
Clinical Relevance Studies
When programs advance to anti-angiogenesis, immunotherapy combination, orthotopic liver therapy, intrahepatic dissemination, lung metastasis, chronic disease background, local therapy, or relapse/MRD stages, Alfa Cytology can further provide orthotopic liver models, metastasis models, syngeneic immunocompetent models, humanized immune models, or induced models to help clients generate evidence more aligned with clinical scenarios.
Liver Cancer Mechanism Research
For liver cancer studies, experimental design typically needs to address cell line stratification, intrahepatic microenvironment, chronic disease background, immune microenvironment, and invasion/metastasis mechanisms simultaneously. Alfa Cytology provides model development, dosing intervention, pathology testing, immunology testing, protein testing, and RNA testing services, covering angiogenesis, hypoxia, EMT, cancer stemness, intrahepatic dissemination, NASH-HCC, immune evasion, TME remodeling, relapse, and MRD clearance.
In Vitro and In Vivo Layered Validation
Animal studies can evaluate whether a candidate inhibits tumor growth, intrahepatic dissemination, lung metastasis, or relapse; zebrafish platforms provide high-throughput in vivo screening covering tumor proliferation, intrahepatic colonization, intrahepatic dissemination, angiogenesis, immune co-culture, and drug toxicity; cell-based experiments validate proliferation, apoptosis, migration and invasion, tube formation, hypoxia, EMT, stemness, drug internalization, and resistance mechanisms.
Molecular Mechanism Studies
Depending on program needs, we offer IHC, IF, flow cytometry, ELISA, Western blot, qPCR, RNA-seq, target expression validation, tumor immune profiling, angiogenesis testing, PK/PD, tumor tissue drug concentration, and liver tissue exposure testing.
For clients with only a candidate drug, target direction, or preliminary mechanistic hypothesis, Alfa Cytology assists in structuring cell line selection, model pathways, group design, dosing regimens, detection endpoints, terminal sample collection, and data presentation，translating R&D questions into executable animal study protocols. Our capabilities support a broad spectrum of therapeutic modalities, including but not limited to:
| R&D Project | Cell Lines | Host System | Preferred Model | Key Endpoints |
| Early efficacy screening and dose exploration | HepG2, Huh7, Hep3B, PLC/PRF/5 | BALB/c nude, NOD-SCID, NSG | Subcutaneous CDX | TGI, RTV, terminal tumor weight, body weight, Ki67, cleaved caspase-3, AFP, PK/PD. |
| High-invasion / high-malignancy efficacy screening | MHCC97L, MHCC97H, HCCLM3, SK-HEP-1 | BALB/c nude, NOD-SCID, NSG | High-invasion subcutaneous CDX, escalation to orthotopic or metastasis models | TGI, RTV, EMT, MMP-2/9, VEGF, HIF-1α, metastasis-related markers. |
| Liver orthotopic microenvironment and anti-angiogenesis | HepG2-luc, Huh7-luc, MHCC97H-luc, HCCLM3-luc, Hepa1-6-luc | BALB/c nude, NOD-SCID, NSG; C57BL/6 immunocompetent mice | Human or syngeneic orthotopic liver model | BLI, ultrasound/MRI, intrahepatic burden, CD31, VEGF, HIF-1α, AFP, survival. |
| TACE / ablation / radiotherapy / local delivery combination | Huh7-luc, MHCC97H-luc, HCCLM3-luc, Hepa1-6-luc | BALB/c nude, NOD-SCID, NSG; C57BL/6 immunocompetent mice | Orthotopic liver model, with relapse/MRD model when needed | Orthotopic burden, liver tissue drug concentration, local necrosis, residual lesions, relapse rate, survival. |
| Intrahepatic dissemination / multifocal liver lesions | MHCC97H-luc, HCCLM3-luc, Hepa1-6-luc | BALB/c nude, NOD-SCID, NSG; C57BL/6 immunocompetent mice | Orthotopic spontaneous dissemination or portal vein-related colonization model | Intrahepatic nodule count, primary/satellite lesion ratio, BLI, liver weight, pathology, survival. |
| Lung metastasis and systemic dissemination | MHCC97H, HCCLM3, SK-HEP-1, Hepa1-6 | BALB/c nude, NOD-SCID, NSG; C57BL/6 immunocompetent mice | Tail vein lung colonization model or orthotopic spontaneous lung metastasis model | Lung nodule count, lung weight, BLI, lung pathology, EMT, MMP, VEGF, survival. |
| NASH / fibrosis / chronic disease background HCC | DEN mice, NASH diet model, fibrosis background model | C57BL/6 or other strains, project-dependent | DEN-induced or NASH-HCC chronic disease background model | Incidence, nodule count, fibrosis, inflammation, steatosis, immune microenvironment, liver function. |
| Immunotherapy and VEGF combined immunotherapy | Hepa1-6/Hepa1-6-luc + C57BL/6; H22/H22-luc + BALB/c; RIL-175 | C57BL/6, BALB/c immunocompetent mice | Syngeneic immunocompetent model, orthotopic preferred | TGI/BLI, CD8/Treg, MDSC, macrophages, cytokines, CD31, VEGF, survival. |
| Human immune-dependent therapies | HepG2, Huh7, Hep3B, MHCC97H, HCCLM3 | huPBMC or huHSC-reconstituted NSG/NOG mice | Humanized immune model | hCD45, hCD3, hCD8, T cell activation, cytokines, tumor burden, xGvHD/CRS risk. |
| Postoperative relapse / post-interventional residual / MRD clearance | Huh7-luc, MHCC97H-luc, HCCLM3-luc, Hepa1-6-luc | BALB/c nude, NOD-SCID, NSG; C57BL/6 immunocompetent mice | Orthotopic liver model with local treatment and relapse follow-up | BLI relapse, local relapse rate, intrahepatic dissemination, lung metastasis, survival, residual lesion markers. |
For liver cancer programs focused on intrahepatic microenvironment and anti-angiogenesis evaluation, we configure TGI, RTV, terminal tumor weight, BLI, ultrasound, MRI, survival, intrahepatic nodules, intrahepatic dissemination, lung metastasis, AFP, ALT/AST, CD31, VEGF, HIF-1α, and liver tissue exposure, highlighting efficacy, angiogenesis, and immune features within the liver organ environment.
Multimodal In Vivo Imaging
Pathology and IHC/IF Staining
TME Microenvironment and Immune Profiling
Alfa Cytology specializes in providing various animal models tailored for liver cancer research. These models are valuable tools to study liver cancer etiology, progression, and therapy.
|
3D Co-cultures
|
Mouse models
Non-mouse models
|
Computational Modeling
|
Alfa Cytology's liver cancer cell line panel covers general efficacy, high-invasion/high-metastasis, liver orthotopic microenvironment, angiogenesis/local therapy, and immuno-oncology, enabling cell line selection and matching based on basic tumor formation capacity, invasion/metastasis capacity, liver orthotopic compatibility, target expression, and immune system requirements.
Basic Tumor Formation and General Efficacy Cell Lines
High-Invasion and High-Metastasis Cell Lines
Angiogenesis, Local Therapy, and Stemness Selection-Related Cell Lines
Alfa Cytology provides end-to-end liver cancer animal model development services, spanning model design, cell line selection, model construction, dosing intervention, efficacy evaluation, pathology, immunology, molecular mechanism testing, and PK/PD analysis. The models below represent our core capabilities across HCC early efficacy screening, liver orthotopic microenvironment, intrahepatic dissemination, lung metastasis, chronic disease background carcinogenesis, immunotherapy, anti-angiogenesis combination, local therapy, and relapse/MRD research. Each model can be customized to match your program's treatment scenario, cell line characteristics, liver organ microenvironment, immune system requirements, administration route, and R&D stage, from early screening to clinical relevance validation.
Subcutaneous Xenograft Model (CDX)
Subcutaneous CDX models typically involve inoculating human hepatocellular carcinoma cells subcutaneously into immunodeficient mice, followed by randomization and dosing once tumors reach a predetermined volume. Commonly used hosts include BALB/c nude, NOD-SCID, and NSG mice. Commonly used cell lines include HepG2, Huh7, Hep3B, PLC/PRF/5, MHCC97L, MHCC97H, HCCLM3, and SK-HEP-1.
Model characteristics
HepG2, Huh7, Hep3B, and PLC/PRF/5 are suitable for early efficacy screening, dose exploration, PK/PD, basic targeted agents, and cytotoxic drug research. MHCC97L, MHCC97H, HCCLM3, and SK-HEP-1 are suitable for high-invasion, advanced resistance, anti-metastasis, and high-malignancy program early screening. This model has high standardization and good reproducibility, suitable for early screening and PK/PD research; its limitations are difficulty in reflecting liver blood supply, liver sinusoidal microenvironment, hypoxia gradient, intrahepatic drug distribution, and immune background.
Modeling and dosing timelines
Subcutaneous CDX typically reaches enrollment volume within 1–4 weeks, with randomization commonly performed at tumor volumes of approximately 80–150 mm³. The conventional treatment period is 2–4 weeks. For sustained-release formulations, continuous dosing, withdrawal rechallenge, or resistance evolution, this can be extended to 4–8 weeks. Small molecules can be dosed daily or every other day; antibodies, ADCs, and long-acting formulations can be dosed weekly or every 2 weeks; chemotherapy and cytotoxic agents require interval dosing based on toxicity window.
Detection endpoints
Recommended positive controls
Sorafenib at 30–60 mg/kg oral daily for 2–4 weeks; lenvatinib at 3–10 mg/kg oral daily for 2–4 weeks. Regorafenib, cabozantinib, or ramucirumab can serve as later-line or mechanism references. Doxorubicin at 2–5 mg/kg IV or IP, once weekly or at intervals; 5-FU at 20–50 mg/kg IP, 1–2 times weekly.
Liver Orthotopic Model
Human liver orthotopic models typically use HepG2-luc, Huh7-luc, MHCC97H-luc, or HCCLM3-luc, inoculated into the liver lobe of NSG or NOD-SCID mice as cells or small tumor fragments. Syngeneic liver orthotopic models typically use Hepa1-6-luc or H22-luc, paired with C57BL/6 or BALB/c mice, respectively. After modeling, dynamic monitoring can be performed via BLI, ultrasound, or MRI.
Model characteristics
HepG2-luc and Huh7-luc are more suitable for general orthotopic efficacy research; MHCC97H-luc and HCCLM3-luc are more suitable for high-invasion, intrahepatic dissemination, and lung metastasis observation; Hepa1-6-luc is more suitable for immunotherapy and liver TME research. This model has high technical requirements, significant inter-batch variability, and low throughput, and is not suitable as a first-round rapid ranking platform for multiple candidates, but is more suitable for intrahepatic microenvironment, local therapy, anti-angiogenesis, immunotherapy combination, intrahepatic dissemination, and relapse research.
Modeling and dosing timelines
Liver orthotopic models typically require 1–3 weeks to form monitorable burden; enrollment confirmation by BLI or imaging is recommended. The conventional treatment observation period can be 2–6 weeks. Local therapy, anti-angiogenesis combination, relapse, or MRD research can be appropriately extended. Treatment can begin after BLI or imaging confirmation of tumor burden. If studying post-local-therapy relapse, local treatment should be performed after orthotopic burden formation, followed by subsequent drug intervention and follow-up.
Detection endpoints
Recommended positive controls
Sorafenib and lenvatinib can serve as basic targeted agent references for orthotopic models. anti-PD-1/PD-L1, anti-CTLA-4, anti-VEGF, or their combinations can be used in syngeneic orthotopic models. Antibody dosing is commonly at 100–200 μg/mouse IP, twice weekly or once every 3 days, for 2–3 consecutive weeks. TACE, ablation, hepatic artery infusion, or local delivery programs can set doxorubicin, local formulations, radiotherapy, or anti-angiogenesis combination controls based on specific protocols.
Intrahepatic Dissemination Model
Intrahepatic dissemination models can be based on MHCC97H-luc, HCCLM3-luc, or Hepa1-6-luc orthotopic models, observing intrahepatic satellite lesions and multifocal expansion after primary lesion formation; intrahepatic colonization can also be enhanced via portal vein-related routes.
Model characteristics
This model is suitable for intrahepatic relapse, intrahepatic multifocal formation, residual lesion expansion after local therapy, and anti-intrahepatic dissemination strategy research.
Detection endpoints
Intrahepatic nodule count, primary/satellite lesion ratio, BLI, liver weight, liver tissue HE, Ki67, EMT markers, MMP-2/9, and survival.
Recommended positive controls
Sorafenib, lenvatinib, regorafenib, and cabozantinib can serve as systemic therapy references according to program stage.
Experimental Lung Metastasis Model
Experimental lung metastasis models typically involve tail vein injection of MHCC97H, HCCLM3, SK-HEP-1, or Hepa1-6 cells.
Model characteristics
This model is suitable for advanced systemic dissemination, lung colonization, and systemic anti-metastasis drug screening. Mainly addresses the lung colonization stage and does not fully represent the natural metastasis cascade.
Detection endpoints
Lung nodule count, lung weight, BLI, lung tissue HE, metastatic area, MMP-2/9, VEGF, EMT markers, and survival.
Recommended positive controls
Sorafenib, lenvatinib, regorafenib, and cabozantinib can serve as systemic therapy references according to program stage. Anti-VEGF agents, TKI combination immunotherapy, or radiotherapy combination can be designed based on the metastasis model.
Spontaneous Lung Metastasis Model
Spontaneous lung metastasis models are typically based on MHCC97H-luc or HCCLM3-luc orthotopic liver cancer models, with long-term observation of primary lesion invasion, hematogenous dissemination, and lung metastasis formation.
Model characteristics
This model is suitable for studying the natural metastasis cascade, perioperative therapy, anti-metastasis maintenance therapy, and long-term relapse risk. Closer to the natural metastasis process, but with longer cycles and greater individual variability.
Detection endpoints
Orthotopic tumor burden, lung BLI signal, lung nodules, lung pathology, intrahepatic dissemination, survival, and metastasis-related molecular markers.
Recommended positive controls
Sorafenib, lenvatinib, regorafenib, and cabozantinib can serve as systemic therapy references according to program stage. Anti-VEGF agents, TKI combination immunotherapy, or radiotherapy combination can be designed based on the metastasis model.
DEN-Induced Model
DEN-induced models induce liver cancer via chemical carcinogenesis, and can be used alone or combined with promoting factors to establish an inflammation, fibrosis, and carcinogenesis continuum.
Model characteristics
This model is suitable for studying liver cancer development, long-term prevention, and the inflammation-fibrosis-carcinogenesis process. The model has long cycles, low throughput, and significant inter-batch variability, and is not suitable for rapid comparison of multiple candidates.
Detection endpoints
Incidence, nodule count, tumor burden, liver weight, ALT/AST, AFP, fibrosis, inflammatory cytokines, Ki67, pathological grading, and carcinogenesis-related pathways.
Recommended positive controls
Long-term prevention or mechanism research can set sorafenib, lenvatinib, anti-inflammatory, or anti-fibrotic references according to objectives.
NASH-HCC Chronic Disease Background Model
NASH-HCC models typically use high-fat, high-sugar, high-cholesterol, choline-deficient amino acid-defined diets or other metabolic stress strategies to form a background of steatosis, inflammation, fibrosis, and carcinogenesis.
Model characteristics
This model is suitable for metabolic-related liver cancer, NASH-HCC, anti-fibrosis combined with anti-tumor, chronic disease comorbidity, and metabolic-immune interaction research.
Detection endpoints
Body weight, liver weight, blood lipids, blood glucose, insulin resistance, ALT/AST, hepatic steatosis, inflammation, fibrosis, tumor nodule count, immune cell infiltration, and metabolomics.
Recommended positive controls
Long-term prevention or mechanism research can set sorafenib, lenvatinib, anti-inflammatory, or anti-fibrotic references according to objectives.
Syngeneic Subcutaneous Model
Hepa1-6 or H22 can be inoculated subcutaneously in C57BL/6 or BALB/c mice, respectively, retaining an intact immune system. Randomization occurs when tumors reach 50–100 mm3, with a treatment period of typically 10–21 days.
Model characteristics
This model is suitable for immunotherapy early screening, combination therapy comparison, and immune mechanism preliminary validation.
Detection endpoints
Tumor volume, TGI, body weight, survival, flow cytometry immune profiling, CD8/Treg, MDSC, macrophages, cytokines, and IHC/IF.
Recommended positive controls
anti-PD-1, anti-PD-L1, or anti-CTLA-4 can be administered IP at 100–200 μg/mouse, twice weekly or once every 3 days, for 2–3 consecutive weeks.
Syngeneic Orthotopic Model
Hepa1-6-luc or H22-luc can be used for syngeneic liver orthotopic models. This model simultaneously retains the liver organ microenvironment and immune system.
Model characteristics
This model is suitable for immunotherapy, anti-angiogenesis combination immunotherapy, local therapy, and relapse research. Murine tumors differ from human liver cancer in target expression and molecular background; human target drugs still require CDX or humanized model supplementary validation.
Detection endpoints
BLI, orthotopic tumor burden, intrahepatic dissemination, survival, CD8/Treg, myeloid cell profile, Kupffer cells, liver sinusoidal endothelial-related markers, cytokines, and single-cell/spatial immune analysis.
Recommended positive controls
anti-PD-1, anti-PD-L1, or anti-CTLA-4 can be administered IP at 100–200 μg/mouse, twice weekly or once every 3 days, for 2–3 consecutive weeks. Anti-VEGF or anti-angiogenic TKI combination immunotherapy can serve as an HCC immunotherapy combination reference. STING agonists, cytokines, or local immune activation agents can be designed based on administration route.
huPBMC Model
The huPBMC model establishes a short-term human immune effector environment by infusing human peripheral blood mononuclear cells into immunodeficient mice, combined with human liver cancer cell lines.
Model characteristics
This model is suitable for bispecifics, TCE, CAR-T/NK, human antibodies, and human immune-dependent drug validation. This model has high cost, long cycles, significant donor variability, and carries xGvHD or cytokine release risk.
Detection endpoints
hCD45, hCD3, hCD4, hCD8, NK cells, T cell activation, tumor infiltration, IFN-γ, TNF-α, IL-6, Granzyme B, tumor burden, body weight, and xGvHD manifestations.
Recommended positive controls
anti-human PD-1, anti-human PD-L1, or other human target antibodies can serve as mechanism references. TCE, CAR-T, or CAR-NK programs should include target-positive, low/negative, effector cell, and empty vector/irrelevant TCE controls. Cell therapy doses are often designed on the order of 106–107 cells/mouse.
huHSC Model
The huHSC model reconstructs a longer-term human immune system via human hematopoietic stem cells, suitable for complex immune microenvironment, human immune cell differentiation, immune resistance, and long-term combination therapy research.
Model characteristics
This model is suitable for long-cycle TCE, CAR-T/NK, bispecifics, immune resistance, and complex TME mechanism validation. This model has high cost, long cycles, significant donor variability, and carries xGvHD or cytokine release risk; it is not recommended as a first-round screening platform.
Detection endpoints
Human immune reconstitution ratio, T/B/NK/myeloid cell spectrum, tumor infiltration, cytokines, human immune checkpoint expression, tumor burden, survival, and major organ pathology.
Recommended positive controls
anti-human PD-1, anti-human PD-L1, or other human target antibodies can serve as mechanism references. TCE, CAR-T, or CAR-NK programs should include target-positive, low/negative, effector cell, and empty vector/irrelevant TCE controls. Cell therapy doses are often designed on the order of 106–107 cells/mouse.
Relapse and Minimal Residual Disease Model
Relapse and MRD models are typically based on Huh7-luc, MHCC97H-luc, HCCLM3-luc, or Hepa1-6-luc orthotopic liver cancer models. First, monitorable intrahepatic tumor burden is established, followed by local therapy, ablation simulation, partial resection, or short-course intervention. Based on program objectives, TACE simulation, local delivery, radiotherapy, ablation simulation, debulking, or withdrawal observation can be set up. Luc-labeled cell lines help track residual disease and relapse processes.
Model characteristics
This model is suitable for postoperative relapse, post-interventional residual disease, perioperative therapy, intrahepatic relapse, MRD clearance, and long-term maintenance therapy research. This model has high requirements for tumor formation window, local treatment timing, monitoring methods, and long-term follow-up, and is not suitable as an early large-scale screening model.
Detection endpoints
Recommended positive controls
Sorafenib, lenvatinib, regorafenib, or cabozantinib can serve as relapse inhibition or maintenance therapy references according to program stage. Syngeneic orthotopic relapse models can set anti-PD-1, anti-PD-L1, anti-CTLA-4, anti-VEGF, or immune combination references. TACE or ablation-related programs can set doxorubicin, local delivery, radiotherapy, or anti-angiogenesis combination references.
By Development Stage
By Drug Type
By Research Objective
By Route of Administration
By Development Pathway
Etiology- & Microenvironment-Driven Modeling
Liver cancer pathogenesis is deeply tied to underlying liver pathology (fibrosis, cirrhosis, NASH/MASH, hepatitis B/C). Alfa Cytology designs tailored evaluation pathways incorporating altered hepatic sinusoidal architecture, hypoxia gradients, and metabolic dysregulation, reflecting realistic drug exposure barriers.
Stratified Cell Line & Syngeneic Directory
Model choice directly influences anti-angiogenic, metabolic, and IO readouts. Alfa Cytology helps clients match appropriate systems—such as HepG2, Huh-7, Hep3B, Hepa1-6, and H22—based on etiology background, viral status, alpha-fetoprotein (AFP) expression, and immune profiles.
Orthotopic Liver & Intrahepatic Metastasis Models
Subcutaneous models lack hepatic dual blood supply, liver-specific metabolic enzymes, and sinusoidal immunity. Alfa Cytology helps clients generate high-fidelity translational evidence through intrahepatic orthotopic implantation and multifocal intrahepatic dissemination models.
Target Validation & Integrated PK/PD Workflows
Programs targeting VEGFR, FGFR4, MET, or TME immune checkpoints require rigorous liver-specific pharmacokinetic evaluation. Alfa Cytology configures hepatic biomarker monitoring, vascular normalization scoring, and integrated PK/PD workflows tailored to liver disease status.
Alfa Cytology is committed to the research and study of cancer, from cell therapy development services, immune checkpoint inhibitor development services, to cancer drug development services, providing one-stop solutions. Our cancer experts have many years of experience in the development of the latest therapies for liver cancer. If you are interested in our service, please contact us.
Reference
For research use only.
Alfa Cytology, a preclinical research solution provider, provides its clients with one-stop solutions to accelerate cancer therapeutics discovery and development.
Copyright © 2026 Alfa Cytology. All rights reserved.
